Alkeus is first and foremost dedicated to patients' rights and safety. If you are interested in learning more about future clinical trials, please send us an email at firstname.lastname@example.org. Alkeus intends to run clinical trials in serious diseases such as the following:
Stargardt disease is a genetic disorder and the leading cause of juvenile blindness affecting about 30,000 people in the USA (1 person in 10,000). Patients with Stargardt are most often diagnosed during their teenage years and vision will rapidly degrade to legal blindness in a few years. This rare genetic disease has no cure or treatment.
As the disease is very rare, patients are hard to find.
Dry-AMD is the leading cause of blindness for people over 50. There is no treatment or cure for dry-AMD. The late form of dry-AMD, also called Geographic Atrophy affects approximately 1 million patients in the USA alone. Patients with Geographic Atrophy have a seriously impaired vision, many patients being legally blind. Only partial peripheral vision is preserved.
The intermediate form of dry-AMD affects approximately 8 million patients in the US alone. The severity of the disease is measured by a retinal specialist who attributes a disease grade (from 1 to 4).
If grade 1 and grade 2 have a relatively little chance of progression to late-AMD (dry or wet forms), grade 3 and grade 4 have respectivaly about 25% and 50% chance of progression to late-AMD after 5 years. These two groups of patients are at high risk of complications resulting of late-AMD.
Retinitis pigmentosa (RP) forms a group of rare diseases that lead to blindness preceded by night blindness
and tunnel vision for several years or decades.
The disease affects approximately 100,000 people in the US.
Although multiple genes when mutated can cause Retinitis Pigmentosa, about 5% of the patients with RP have mutated ABCA4 genes, which leads to improper processing of vitamin A by the eye. These patients could potentially benefit from Alkeus' technology.